The MS-STAT2 trial of a high-dose simvastatin has failed to slow progression of disability in patients with secondary ...

often stop taking disease-modifying therapy as they transition from relapsing-remitting MS to secondary progressive MS. This study shows that people who stop stop disease-modifying therapy have higher ...

In addition to the overall PMS population, the data would also deliver insights on its sub-forms, including non-relapsing secondary progressive MS, a subtype with the highest unmet medical need.

But tolebrutinib showed something novel at ECTRIMS. In the phase III HERCULES trial, tolebrutinib slowed confirmed disability ...

NEW YORK, November 7, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and ...

Positive Interim Analysis of Phase 3 ENSURE Program, Unblinded Independent Data Monitoring Committee Confirmed that Predetermined Futility Criteria Have Not Been Met and Recommended Trials Should ...

Christina Applegate suffers from multiple sclerosis (MS) - a condition that affects the brain and spinal cord. There are three types of MS and each can manifest in different ways ...

Drugmakers had hoped that inhibiting receptor-interacting protein kinase would decrease inflammation and reduce neuronal degeneration in patients with multiple sclerosis and other neurodegenerative co ...

So i just love being with the children,” said Lee-Ballou. She was diagnosed with secondary progressive multiple sclerosis in 2010, just before her 40th birthday. “I woke up one morning and I w ...

A new drug for people who have one of the worst forms of multiple sclerosis aims to make treatment much easier for patients. Ocrevus is a medicine commonly used to treat primary progressive MS ...

Tolebrutinib was found to delay disability progression in patients with non-relapsing secondary progressive multiple sclerosis (nrSPMS), according to results from the HERCULES study. In this phase 3 ...

Sanofi has ended a Phase 2 clinical trial into oditrasertib, an investigational RIPK1 inhibitor therapy, in people with relapsing and progressive multiple sclerosis (MS) after it failed to meet ...